Original reporting and analysis on the stories shaping biotech.
The FDA pushed Orca Bio's decision on Orca-T back three months to July 2026, citing a manufacturing paperwork update. With Phase 3 data showing a massive survival advantage over standard transplants, the delay adds Orca Bio to a growing list of biotech companies caught in regulatory limbo.
A $6 million biotech shell just became a $380 million Alzheimer's play through a reverse merger, and Cyclerion's stock surged 350% on the news. Korsana Biosciences is betting its brain-penetrating antibody can outperform Leqembi and Kisunla, but it hasn't even started human testing yet.
Nearly 8,000 clinical trial sites across the Middle East have been knocked offline by the escalating conflict, threatening thousands of active studies and the patients enrolled in them. The fallout could delay drug approvals worldwide, and every major pharma company is exposed.
A Boulder, Colorado biotech you've never heard of just raised $100 million without testing its drug in a single person. Ambrosia Biosciences is betting its oral GLP-1 pill can compete in the most crowded race in pharma, and investors are lining up to fund that bet.
United Therapeutics' lung drug Tyvaso just posted blockbuster results in a disease it was never originally designed to treat. The IPF data could double the drug's market, and Wall Street is already doing the math.
Immunovant's FcRn inhibitor batoclimab just struck out in two Phase 3 trials for thyroid eye disease, sending shares tumbling and raising hard questions about whether this entire drug class can crack TED. The company is betting its future on a next-gen molecule, but the clock is ticking.
U.S. venture capital firms are embedding in Chinese labs and writing checks before research data is even published. The strategy has produced billion-dollar exits, but the geopolitical risks are as big as the potential rewards.
The first-ever tRNA therapy just entered the clinic, and it doesn't care what disease you have. Alltrna's AP003 could become the foundation of a disease-agnostic genetic medicine platform, but the road from first-in-human trial to approved drug is anything but simple.
Eli Lilly is spending up to $7.8 billion to acquire Centessa Pharmaceuticals and its pipeline of sleep-disorder drugs. It's Lilly's third acquisition of 2026, and it signals that the race to dominate neuroscience is getting very expensive, very fast.
NIH Director Jay Bhattacharya quoted the father of American science funding at CPAC to defend the Trump administration's research overhaul. Scientists say he got the history exactly backward, and the real-world numbers back them up.
Takeda is cutting 634 U.S. jobs to save $1.25 billion, funneling the cash into three make-or-break drug launches. It's the latest chapter in Big Pharma's industry-wide belt-tightening, and 2,500+ employees have already felt the squeeze.
Novo Nordisk is accusing KBP Biosciences of hiding damning clinical data before a $1.3 billion licensing deal, while KBP says Novo simply didn't read the files it had access to. With $830 million in damages at stake and a worldwide asset freeze already in place, this fight could reshape how pharma does deals.
A small biotech called Oric Pharmaceuticals is heading into a massive Phase 3 trial for prostate cancer, armed with preclinical data showing its drug outperforms Pfizer's rival molecule. The $16 billion prostate cancer market just got a lot more interesting.
A nine-patient trial from an AI-driven startup just produced eczema data that rivals Sanofi's $15 billion blockbuster Dupixent. The catch? It's a once-daily pill, not an injection, and the real tests are just beginning.
IO Biotech went from a $100M IPO and "most innovative biotech" honors to total Chapter 7 liquidation in five years, all because its cancer vaccine trial missed statistical significance by the thinnest of margins. It's the most brutal cautionary tale in immuno-oncology right now.
Biogen is paying a 140% premium to acquire Apellis Pharmaceuticals in a $5.6 billion all-cash deal, its biggest acquisition in years. The move completes a three-year strategy to build a complement disease powerhouse, and it tells you everything about where big pharma thinks the future of immunology is headed.
Bicycle Therapeutics cut 30% of its staff and shelved its bladder cancer drug after the FDA demanded more proof it could beat Pfizer's Padcev. Now the company is betting its future on pancreatic cancer and radioactive missiles.
Takeda just axed 634 U.S. jobs, bringing its two-year layoff total to roughly 2,500. The company is spending nearly a billion dollars on restructuring to save $1.3 billion a year, but everything hinges on whether its next wave of drugs can replace the revenue that's already slipping away.
Blackstone just closed a $6.3 billion life sciences fund, the largest dedicated vehicle of its kind ever raised. In a market where biotech fundraising hit multi-year lows, the oversubscribed mega-fund tells a fascinating story about where institutional money is actually flowing.
Merck is spending $6.7 billion on a cancer drug that's still in early trials, and the logic behind it says everything about how desperate Big Pharma gets when a $30 billion product is about to lose patent protection.
Merck just showed that a daily pill can lower cholesterol as well as the injectable drugs patients keep quitting. With 97% adherence and a nearly 60% LDL reduction, enlicitide could upend the $3 billion PCSK9 inhibitor market.
For 20 years, kids with Hunter syndrome had a treatment that could help their bodies but couldn't reach their brains. Denali Therapeutics just got FDA approval for the first biologic designed to cross the blood-brain barrier, and the implications go way beyond one rare disease.
Join thousands of biotech professionals who start their day with our free, daily briefing.